Ironwood Pharmaceuticals Inc. (IRWD)

13.40
NASDAQ : Health Technology
Prev Close 13.62
Day Low/High 13.10 / 14.13
52 Wk Low/High 9.07 / 21.20
Avg Volume 1.45M
Exchange NASDAQ
Shares Outstanding 154.65M
Market Cap 2.11B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Ironwood Announces Effectiveness Of Cyclerion Form 10 Registration Statement

Ironwood Announces Effectiveness Of Cyclerion Form 10 Registration Statement

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.

Ironwood Pharmaceuticals To Present At Cowen Health Care Conference

Ironwood Pharmaceuticals To Present At Cowen Health Care Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 39 th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.

Cyclerion, The Planned R&D Spin-off Of Ironwood Pharmaceuticals, Secures Commitments Of $175 Million In Private Offering

Cyclerion, The Planned R&D Spin-off Of Ironwood Pharmaceuticals, Secures Commitments Of $175 Million In Private Offering

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals To Present At SVB Leerink Global Healthcare Conference

Ironwood Pharmaceuticals To Present At SVB Leerink Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2018 Investor Update

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2018 Investor Update

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2018 results and recent business activities.

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2018 Investor Update Call

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2018 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2018 investor update conference call and webcast at 8:30 a.

Ironwood Announces Filing Of Form 10 Registration Statement In Connection With Planned Business Separation

Ironwood Announces Filing Of Form 10 Registration Statement In Connection With Planned Business Separation

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the filing by Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals Announces Board Of Directors For Ironwood And Cyclerion, Effective Following Separation

Ironwood Pharmaceuticals Announces Board Of Directors For Ironwood And Cyclerion, Effective Following Separation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the composition of the Ironwood and Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals Initiates Phase 1 Trial Of IW-6463, The First CNS-penetrant SGC Stimulator To Enter Clinical Trials

Ironwood Pharmaceuticals Initiates Phase 1 Trial Of IW-6463, The First CNS-penetrant SGC Stimulator To Enter Clinical Trials

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers.

Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In China For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In China For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today announced that the National Medical Products Administration (NMPA) approved the marketing application for LINZESS® (linaclotide) for adults with irritable bowel...

Michael Shetzline (Photo: Business Wire)

Michael Shetzline (Photo: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that Michael Shetzline, M.

Mark Mallon (Photo: Business Wire)

Mark Mallon (Photo: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the Ironwood board of directors has appointed chief executive officers (CEOs) of the two companies, effective at the time of Ironwood's planned separation which is on track to be completed...

Interesting IRWD Put And Call Options For August 16th

Interesting IRWD Put And Call Options For August 16th

Investors in Ironwood Pharmaceuticals Inc saw new options begin trading this week, for the August 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 224 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 37 th Annual J.

Ironwood And Allergan Announce Settlement With Mylan Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood And Allergan Announce Settlement With Mylan Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc.

Ironwood Pharmaceuticals To Present At 27th Annual Credit Suisse Healthcare Conference

Ironwood Pharmaceuticals To Present At 27th Annual Credit Suisse Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 27 th Annual Credit Suisse Healthcare Conference on Wednesday, November 14 th, 2018 at 2:15 p.

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today provided an update on its third quarter 2018 results and recent business activities.

Ironwood Pharmaceuticals To Host Third Quarter 2018 Investor Update Call

Ironwood Pharmaceuticals To Host Third Quarter 2018 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2018 investor update conference call and webcast at 8:30 a.

Ironwood Pharmaceuticals Presenting IW-3718 And Linaclotide Data At The American College Of Gastroenterology 2018 Annual Scientific Meeting

Ironwood Pharmaceuticals Presenting IW-3718 And Linaclotide Data At The American College Of Gastroenterology 2018 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology 2018...

First Week Of May 2019 Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week Of May 2019 Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc saw new options begin trading this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ironwood Pharmaceuticals Announces FDA Fast Track Designation For Praliciguat For The Treatment Of Heart Failure With Preserved Ejection Fraction (HFpEF)

Ironwood Pharmaceuticals Announces FDA Fast Track Designation For Praliciguat For The Treatment Of Heart Failure With Preserved Ejection Fraction (HFpEF)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:55 p.

First Week Of IRWD October 19th Options Trading

First Week Of IRWD October 19th Options Trading

Investors in Ironwood Pharmaceuticals Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IRWD options chain for the new October 19th contracts and identified the following call contract of particular interest.

Approval Of Linzess® Tablets 0.25 Mg In Japan For Additional Indication Of Chronic Constipation

Approval Of Linzess® Tablets 0.25 Mg In Japan For Additional Indication Of Chronic Constipation

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

Ironwood Pharmaceuticals, Inc. (Nasdaq:IRWD), a commercial biotechnology company, today provided an update on its second quarter 2018 results and recent business activities.

Ironwood Pharmaceuticals To Host Second Quarter 2018 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2018 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.

Ironwood Pharmaceuticals Initiates Phase IIIb Study Of Linaclotide In Adult Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals Initiates Phase IIIb Study Of Linaclotide In Adult Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced the initiation of a Phase IIIb clinical trial evaluating the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in addition to pain,...

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact On Metabolic And Cardiovascular Clinical Endpoints At The American Diabetes Association's 78th Scientific Sessions

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact On Metabolic And Cardiovascular Clinical Endpoints At The American Diabetes Association's 78th Scientific Sessions

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today presented additional data from an exploratory Phase IIa study of praliciguat (IW-1973) in patients with type 2 diabetes and hypertension during an oral session at the...

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program For IW-3718 In Persistent Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program For IW-3718 In Persistent Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD).

TheStreet Quant Rating: D- (Sell)